In this Research Rundown, we will discuss a 2022 study that focuses on how Hyperbaric Oxygen Therapy Improves Parkinson’s Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1a Pathway.
- The Abstract of this study states the following:
Hyperbaric oxygen therapy (HBOT) has been suggested as a potential adjunctive therapy for Parkinson’s disease (PD).
- The Conclusion of the study states the following:
The effects of HBOT in MPTP-treated mice might come from promoting mitochondrial biogenesis, decreasing apoptotic signaling and attenuating inflammatory mediators in the midbrain, suggesting its potential benefits in PD treatment.
- Our host, di Girolamo likes this study and recommends you review it since it’s a newer study and it focuses on a debilitating, progressive neurodegenerative disease that affects motor function in approximately 1% of the population 60+ years old.
- This is an animal study study using MPTP-Treated mice.
- HBOT was found to —
- Attenuate apoptosis of midbrain tissue in MPTP-treated mice
- Improve motor activity and grip strength in the MPTP-treated mice.
- Reduced substantia nigra dopaminergic neuronal loss in MPTP-treated mice
- Inhibit neuroinflammation in the brain of MPTP-treated mice
- Promote mitochondrial biogenesis through the SIRT-1/PGC-1a pathway in MPTP-treated mice
- This study shows that Hyperbaric Oxygen Therapy should certainly be considered for someone who is struggling with Parkinson’s Disease.